title: From molecule to market access: drug regulatory science as an upcoming discipline.
abstract: Regulatory science as a discipline has evolved over the past years with the object to boost and promote scientific rationale behind benefit/risk and decision making by regulatory authorities. The European Medicines Agency, EMA, the Food and Drug Administration, FDA, and the Japanese Pharmaceutical and Medical Devices Agency, PMDA, highlighted in their distinct ways the importance of regulatory science as a basis of good quality assessment in their strategic plans. The Medicines Evaluation Board, MEB, states: 'regulatory science is the science of developing and validating new standards and tools to evaluate and assess the benefit/risk of medicinal products, facilitating sound and transparent regulatory decision making'. Through analysis of regulatory frameworks itself and their effectiveness, however, regulatory science can also advance knowledge of these systems in general. The comprehensive guidance that is issued to complete an application dossier for regulatory product approval has seldomly been scrutinized for its efficiency. Since it is the task of regulatory authorities to protect and promote public health, it is understood that they take a cautious approach in regulating drugs prior to market access. In general, the authorities are among the first to be blamed if dangerous or useless drugs were allowed to the market. Yet, building a regulatory framework that is not challenged continuously in terms of deliverables for public health and cost-effectiveness, might be counterproductive in the end. Regulatory science and research can help understand how and why regulatory decisions are made, and where renewed discussions may be warranted. The MEB supports regulatory science as an R&D activity to fuel primary regulatory processes on product evaluation and vigilance, but also invests in a 'looking into the mirror' approach. Along the line of the drug life-cycle, publicly available data are reviewed and their regulatory impact highlighted. If made explicit, regulatory research can open the door to evidence based regulatory practice and serve the regulator's contribution to innovative drug licensing today.
authors.affiliation: Medicines Evaluation Board, The Netherlands. Electronic address: cc.gispen@cbg-meb.nl.
authors.forename: Christine C
authors.initials: CC
authors.lastname: Gispen-de Wied
authors.affiliation: Medicines Evaluation Board, The Netherlands.
authors.forename: Hubertus G M
authors.initials: HGM
authors.lastname: Leufkens
mesh_terms: D000818:Animals; D055317:Evidence-Based Practice; D006077:Government Agencies; D006801:Humans; D004364:Pharmaceutical Preparations; D012449:Safety; D012926:Social Control, Formal / Q000379:methods*
chemical_list: D004364:Pharmaceutical Preparations
keywords: Benefit-risk assessment; Drug development; Market authorization; Post-marketing surveillance; Regulatory science